Story

DiaSorin Stock Slides After UBS Downgrade to 'Sell' on Competition Fears

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
DiaSorin Stock Slides After UBS Downgrade to 'Sell' on Competition Fears
Text size
Background

Shares of Italian diagnostics company DiaSorin S.p.A. (BIT: DIA) fell 3.8% to €73.68 in Tuesday trading after analysts at UBS downgraded the stock to "Sell" from a previous "Neutral" rating, expressing caution over the company's growth prospects.

UBS Cites Competitive Headwinds

The downgrade was accompanied by a nearly 17% cut to UBS's price target for DiaSorin, now set at €55. In a note to clients, the investment bank highlighted several key concerns that challenge consensus expectations for sustained, above-market growth.

Key drivers for the more bearish outlook include:

  • Growing competition and policy headwinds in China for DiaSorin's core immunodiagnostics business.
  • Skepticism that the company's new Liaison Nes molecular diagnostics platform can capture enough market share to meet current expectations.
  • A valuation premium of 15% over its peer, bioMérieux, which UBS views as unjustified.
Sample IUX Markets – In-articleAd

UBS analysts now estimate that DiaSorin's 2026 earnings before interest and taxes (EBIT) will come in 4% to 6% below the market consensus, reflecting these challenges.

Market Impact and Context

The sell-off pushed DiaSorin's stock further below its 52-week high of €92.32, underscoring a significant de-rating for the company over the past year. The pressure on the stock was company-specific, as there was no notable weakness in its home benchmark, the Italian FTSE MIB, to drive the decline.

The broader sentiment for the European healthcare diagnostics sector has been cautious, according to the report, amid macroeconomic uncertainty and pressures on healthcare spending. The UBS note adds to investor concerns that have lingered since the company's July earnings update.

Read next

More on Stocks
Back to latest news

LATEST